Form 4: Xilio Therapeutics Director Christina Rossi Granted Significant Stock Options

Xilio Therapeutics, Inc. Director Christina Rossi was granted 31,000 stock options with an exercise price of $0.693, aligning her interests with shareholder value.

Summary

• Christina Rossi, a Director of Xilio Therapeutics, Inc. (XLO), was granted 31,000 stock options on June 11, 2025.
• The exercise price for these options is $0.693 per share.
• The options will vest 100% on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders following the grant date.
• Vesting is contingent upon Ms. Rossi's continued service to Xilio Therapeutics through the vesting date.
• The options have an expiration date of June 10, 2035.
• Following this transaction, Ms. Rossi beneficially owns 31,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is positive as the grant aligns the director's interests with shareholders, which is generally viewed favorably. It's a routine compensation event, not indicative of immediate operational or financial distress.

Positives

• The grant of stock options to Director Christina Rossi aligns her financial interests directly with the long-term performance and shareholder value of Xilio Therapeutics.
• Equity compensation is a standard practice that incentivizes directors to contribute to the company's growth and success.

Negatives

• While not an immediate negative, the future exercise of these options could lead to a slight dilution of existing common stock, although this is a common aspect of equity compensation plans.

Risks

• The value of the stock options is subject to the future market price of Xilio Therapeutics' common stock; if the stock price does not exceed the exercise price, the options may not be valuable.
• Vesting of the options is subject to the Reporting Person's continued service to the Issuer, meaning the options could be forfeited if service ceases before the vesting date.

Future Outlook

The stock option grant indicates a continued commitment to incentivizing key personnel through equity, suggesting an ongoing strategy to align management and director interests with long-term shareholder value creation.

Industry Context

The granting of stock options to directors is a common and widely accepted practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to attract and retain talent and align interests with company performance.

Comparison to Industry Standards

• Equity compensation, such as stock option grants, is a standard component of director remuneration across the biotech and pharmaceutical sectors, comparable to practices seen in companies like Moderna, BioNTech, or Regeneron Pharmaceuticals, which frequently use equity to incentivize leadership.
• The vesting schedule, tied to continued service and an annual meeting, is typical for director grants, ensuring ongoing commitment.
• The exercise price being set at a specific value (likely market price at grant) is also standard for non-qualified stock options.

Related Party Transactions

• The grant of 31,000 stock options to Christina Rossi, a Director of Xilio Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's incentives with shareholder interests, potentially leading to better long-term performance. However, future exercise could lead to minor dilution.
• Director (Christina Rossi): Receives a significant equity incentive, tying her personal financial success to the company's stock performance.

Next Steps

• The stock options will vest on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders, subject to continued service.
• Upon vesting, Christina Rossi will have the right to exercise the options to purchase 31,000 shares of Xilio Therapeutics common stock at the exercise price of $0.693 per share.

Key Dates

Keywords

Xilio Therapeutics, XLO, stock option, director compensation, insider transaction, Form 4, equity compensation, corporate governance